Join
Live feed
·
PRReleasevia Quantisnow
TuHURA Biosciences Inc. logo

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

ByQuantisnow·Wall Street's wire, on your screen.
HURA· TuHURA Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HURA (TuHURA Biosciences Inc.) and more on Quantisnow.